SVLS makes London hire

US venture capital firm SV Life Sciences has appointed Dr Hamish Cameron as a venture partner in its London office, from where he will focus on therapeutic investments in Europe and the United States.

Before joining SVLS, Cameron was appointed CEO of Cambridge Antibody Technology, following its acquisition by Astra Zeneca in 2006. Prior to that, he held a series of senior positions at Astra Zeneca including head of the cardiovascular therapy area, global head of medical tesearch and member of the R&D leadership team. Cameron started his industry career with Janssen, after working as a physician in the UK.